Mindfulness retreat linked to DNA changes in Alzheimer's genes

A meditation study that reaches beyond mood and attention

Mindfulness research has spent years building its case with stress scores, attention tasks, and symptom changes. This study pushes the conversation somewhere much more technical: into blood-based DNA methylation in genes linked to Alzheimer’s disease. With just 17 long-term meditators and 17 sex- and age-matched controls, it is a small proof of concept, but it is the kind of paper that hints at where the field may be headed.

The team, including Idoia Blanco-Luquin, Mónica Macías, Ibai Marro, Marta Puebla-Guedea, Blanca Acha, Johana Álvarez-Jiménez, Sara Razquin-Sola, Miren Roldan, Eneko Cabezon-Arteta, Lidia González-Villena, Jesús Montero-Marín, Javier García-Campayo, Maite Mendioroz, María Jesús Álvarez-López, and collaborators across Spain and the United States, examined whether an intensive contemplative experience could leave measurable marks in Alzheimer’s-related biology. The study was published in *Mindfulness* on May 27, 2026, after circulating as a bioRxiv preprint, and the paper states plainly that it was not preregistered.

What the retreat participants did, and what was measured

The meditators took part in a 1-month Vipassana retreat, which gives this study its particular intensity. Rather than relying on self-report alone, the researchers analyzed blood DNA methylation using bisulfite pyrosequencing, a targeted method suited to examining specific genomic sites with precision. They focused on a panel of Alzheimer’s-related genes: ABCA7, ADAM10, APOE, HOXA3, NXN, TREM2, and TREML2.

That detail matters because the study is not claiming a sweeping change across the whole genome. It is asking a narrower, more disciplined question: can a sustained mindfulness retreat shift methylation in genes already implicated in neurodegeneration? In that sense, the design is more mechanistic than many earlier meditation studies, and it is exactly why the paper is drawing attention inside and outside the mindfulness world.

The methylation signal the authors saw

The main result was not a dramatic overhaul, but a pattern. Compared with the control group, meditators showed increased methylation in ADAM10, APOE, HOXA3, and TREM2. After the retreat, significant differences were also seen for ABCA7, ADAM10, APOE, and HOXA3.

The authors go a step further with two of those genes. They say ADAM10 and HOXA3 changed in the opposite direction to patterns typically seen in Alzheimer’s disease, which raises the possibility of a protective epigenetic shift. That is the most intriguing part of the study, and also the part that needs the most restraint. A methylation pattern that looks directionally interesting is not the same thing as a clinical benefit, and it does not tell us whether neurons are safer, cognition is preserved, or dementia risk is actually lower.

Why this is exciting, but not conclusive

The study lands in a field where DNA methylation is increasingly treated as a meaningful biomarker in Alzheimer’s research. That makes the result feel timely, especially when dementia remains a huge global health burden. The World Health Organization reported that 57 million people worldwide were living with dementia in 2021, with nearly 10 million new cases each year and more than 60 percent of cases in low- and middle-income countries. In the United States, the Alzheimer’s Association estimated that 7.2 million Americans age 65 and older had Alzheimer’s dementia in 2025.

Those numbers explain why even a small biomarker paper gets serious attention. But the right reading is cautious: this is blood-based, preliminary, and not evidence that mindfulness prevents or treats Alzheimer’s disease. The sample was tiny, the study was exploratory, and the paper’s own lack of preregistration makes it best treated as hypothesis-generating rather than confirmatory.

How it fits with the broader meditation science literature

This is not the first time meditation has been linked to biological change. Earlier work on a month-long silent meditation retreat found differential changes in genes involved in chromatin modulation and inflammation, including downregulation of the TNF pathway. Other studies have reported shifts in the methylome and in epigenetic age-related measures among long-term meditators. Reviews have also tracked mindfulness-based interventions across the hypothalamic-pituitary-adrenal axis, serotonergic transmission, aging biomarkers, and neurological markers.

Seen in that context, the new Alzheimer’s-gene paper does not come out of nowhere. It belongs to a maturing research thread that is moving mindfulness away from a purely psychological frame and toward a more integrated model of mind-body biology. The presence of names like Perla Kaliman, Clifford D. Saron, Ayman Mukerji Househam, Quinn A. Conklin, Marta Cosín-Tomás, Grant S. Shields, Brandon G. King, and Anthony P. Zanesco in the wider conversation also signals how interdisciplinary this area has become, spanning contemplative science, molecular biology, and aging research across institutions in Navarra, Barcelona, Sacramento, Davis, Fayetteville, Miami, New York, Chicago, Oxford, Geneva, and beyond.

What readers should take from it now

For mindfulness practitioners, the practical takeaway is not that a retreat has been shown to ward off dementia. It is that the field is beginning to ask whether sustained contemplative practice may leave measurable biological signatures in pathways relevant to neurodegeneration. That is a meaningful shift, because it suggests the science of mindfulness is broadening from symptom relief into biomarker research.

The strongest, most honest reading of this paper is simple: a 1-month Vipassana retreat was associated with methylation changes in a handful of Alzheimer’s-related genes, including ADAM10, APOE, HOXA3, TREM2, and ABCA7. That is exciting as a signal of where the research may head next, especially in a field as urgent as dementia, but it is not proof that mindfulness changes disease course. The real value of the study is that it opens a more rigorous next question, and for now, that is exactly where the evidence should stay.